GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Shiller PE Ratio

OncoSec Medical (FRA:ONMA) Shiller PE Ratio : (As of Oct. 31, 2024)


View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


OncoSec Medical Shiller PE Ratio Historical Data

The historical data trend for OncoSec Medical's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Shiller PE Ratio Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoSec Medical's Shiller PE Ratio

For the Biotechnology subindustry, OncoSec Medical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Shiller PE Ratio falls into.



OncoSec Medical Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

OncoSec Medical's E10 for the quarter that ended in Jan. 2023 is calculated as:

For example, OncoSec Medical's adjusted earnings per share data for the three months ended in Jan. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2023 (Change)*Current CPI (Jan. 2023)
=-2.459/126.2230*126.2230
=-2.459

Current CPI (Jan. 2023) = 126.2230.

OncoSec Medical Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201304 -33.792 98.107 -43.476
201307 -57.147 98.557 -73.189
201310 -32.252 98.536 -41.314
201401 -32.296 98.692 -41.305
201404 -58.934 100.023 -74.371
201407 -48.774 100.520 -61.245
201410 -57.281 100.176 -72.175
201501 -71.980 98.604 -92.142
201504 -97.574 99.824 -123.378
201507 -95.990 100.691 -120.330
201510 -92.129 100.346 -115.887
201601 -85.100 99.957 -107.462
201604 -71.713 100.947 -89.669
201607 -71.676 101.524 -89.114
201610 -57.930 101.988 -71.696
201701 -55.836 102.456 -68.788
201704 -45.157 103.167 -55.249
201707 -51.500 103.278 -62.942
201710 -48.677 104.070 -59.039
201801 -55.924 104.578 -67.499
201804 -35.501 105.708 -42.391
201807 -43.125 106.324 -51.196
201810 -26.222 106.695 -31.021
201901 -25.632 106.200 -30.465
201904 -20.167 107.818 -23.610
201907 -11.382 108.250 -13.272
201910 -18.297 108.577 -21.271
202001 -25.174 108.841 -29.194
202004 -9.108 108.173 -10.628
202007 -4.785 109.318 -5.525
202010 -9.163 109.861 -10.528
202101 -6.683 110.364 -7.643
202104 -4.598 112.673 -5.151
202107 -5.397 115.183 -5.914
202110 -4.754 116.696 -5.142
202201 -4.897 118.619 -5.211
202204 -3.260 121.978 -3.373
202207 -4.541 125.002 -4.585
202210 -4.572 125.734 -4.590
202301 -2.459 126.223 -2.459

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OncoSec Medical  (FRA:ONMA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


OncoSec Medical Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical Headlines

No Headlines